Skip to main content

REVIEW article

Front. Med.
Sec. Precision Medicine
Volume 11 - 2024 | doi: 10.3389/fmed.2024.1463976
This article is part of the Research Topic Nanomedicine Targeting Central Nervous System View all articles

Recent developments in intranasal drug delivery of nanomedicines for the treatment of neuropsychiatric disorders

Provisionally accepted
Anglina Kisku Anglina Kisku 1Ambresh Nishad Ambresh Nishad 1Saurabh Agrawal Saurabh Agrawal 1Rishi Paliwal Rishi Paliwal 2Ashok K. Datusalia Ashok K. Datusalia 3Gaurav Gupta Gaurav Gupta 4,5,6SACHIN K. SINGH SACHIN K. SINGH 7,8Kamal Dua Kamal Dua 8,9*KUNJBIHARI SULAKHIYA KUNJBIHARI SULAKHIYA 1*
  • 1 NeuroPharmacology Research Laboratory (NPRL), Department of Pharmacy, Indira Gandhi National Tribal University,, Amarkantak, Madhya Pradesh,, India
  • 2 Nanomedicine and Bioengineering Research Laboratory (NBRL), Department of Pharmacy, Indira Gandhi National Tribal University,, Amarkantak, Madhya Pradesh,, India
  • 3 Laboratory of Molecular NeuroTherapeutics. Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER),, Rae Bareily, Uttar Pradesh,, India
  • 4 School of Pharmacy, Gyan Vihar University, Jaipur, Rajasthan, India
  • 5 Center for Transdisciplinary Research, Saveetha Institute of Medical and Technical Science, Saveetha University,, Chennai,, India
  • 6 Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University,, Dehradun,, India
  • 7 School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India
  • 8 Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology,, Sydney, Ultimo-NSW,, Australia
  • 9 Discipline of Pharmacy, Graduate School of Health, University of Technology,, Sydney, Ultimo-NSW,, Australia

The final, formatted version of the article will be published soon.

    Neuropsychiatric disorders are multifaceted syndromes with confounding neurological explanations. It includes anxiety, depression, autism spectrum disorder, attention deficit hyperactivity disorder, schizophrenia, Tourette's syndrome, delirium, dementia, vascular cognitive impairment, and apathy etc. Globally, these disorders occupy 15% of all diseases. As per the WHO, India has one of the largest populations of people with mental illnesses worldwide.The blood-brain barrier (BBB) makes it extremely difficult to distribute medicine to target cells in the brain tissues.However, it is possible through novel advancements in nanotechnology, molecular biology, and neurosciences. One such cutting-edge delivery method, nose-to-brain (N2B) drug delivery using nanoformulation (NF), overcomes traditional drug formulation and delivery limitations. Later offers more controlled drug release, better bioavailability, improved patient acceptance, reduced biological interference, and circumvention of BBB. When medicines are delivered via the intranasal (IN) route, they enter the nasal cavity and go to the brain via connections between the olfactory and trigeminal nerves and the nasal mucosa in N2B. Delivering phytochemical, bioactive and synthetic NF is being investigated with the N2B delivery strategy. The mucociliary clearance, enzyme degradation, and drug translocations by efflux mechanisms are significant issues associated with N2B delivery. This review article discusses the types of neuropsychiatric disorders and their treatment with plant-derived as well as synthetic drug-loaded NFs administered via the IN-delivery system. In conclusion, this review provided a comprehensive and critical overview of the IN applicability of plant-derived NFs for psychiatric disorders.

    Keywords: Nanoformulation, Intranasal drug delivery, Phytochemical and Synthetic nanoformulation, Nanomedicines, Neuropsychiatric disorder.

    Received: 12 Jul 2024; Accepted: 29 Aug 2024.

    Copyright: © 2024 Kisku, Nishad, Agrawal, Paliwal, Datusalia, Gupta, SINGH, Dua and SULAKHIYA. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Kamal Dua, Discipline of Pharmacy, Graduate School of Health, University of Technology,, Sydney, Ultimo-NSW,, Australia
    KUNJBIHARI SULAKHIYA, NeuroPharmacology Research Laboratory (NPRL), Department of Pharmacy, Indira Gandhi National Tribal University,, Amarkantak, Madhya Pradesh,, India

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.